Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	42.12B +5.2%
Revenue (ttm)	20.76B +45.2%
Net Income	771.03M +207.2%
EPS	0.14
Shares Out	4.50B
PE Ratio	65.10
Forward PE	n/a
Dividend	0.05 (0.52%)
Ex-Dividend Date	n/a

Volume	n/a
Open	9.36
Previous Close	9.36
Day's Range	9.36 - 9.36
52-Week Range	7.12 - 14.93
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. In addition, it manufactures, tra...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 678
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2025, IST:GENIL's revenue was 19.18 billion, a decrease of -0.59% compared to the previous year's 19.29 billion. Earnings were 814.44 million, an increase of 318.50%.